Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A retrospective, multicenter study assessing the efficacy and safety ramucirumab and docetaxel in previously treated patients with squamous cell lung cancer

Trial Profile

A retrospective, multicenter study assessing the efficacy and safety ramucirumab and docetaxel in previously treated patients with squamous cell lung cancer

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Docetaxel (Primary) ; Ramucirumab (Primary)
  • Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
  • Focus Therapeutic Use

Most Recent Events

  • 11 Feb 2023 Results assessing sequencing strategies of ramucirumab and docetaxel following prior treatments, including immune checkpoint inhibitor (ICI), cytotoxic agent alone, bevacizumab, and tyrosine kinase inhibitor (TKI), published in the European Journal of Clinical Pharmacology.
  • 20 Jan 2022 New trial record
  • 13 Jan 2022 Primary endpoint (progression-free survival) not met according to the results published in the investigational new drugs

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top